Journey Medical 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Journey Medical reported 3rd quarter 2026 total revenue of $19 million, compared with $15 million in the 3rd quarter of 2025, and described the increase as 8%; net product sales increased 11% year over year.
- Emrosi generated $9 million in net revenue, with approximately 40,000 prescriptions in the 3rd quarter, up from about 36,000 in the 2nd quarter, and more than 5,000 unique prescribers.
- Gross margin was 69%, compared with 67% in the 3rd quarter of 2025; SG&A expenses were $12.6 million, including a one-time $1.7 million vendor settlement expense.
- GAAP net loss narrowed to $1.3 million, or $0.05 per share basic and diluted, from $3.9 million, or $0.14 per share basic and diluted, in 3Q 2025.
- EBITDA and adjusted EBITDA were positive; adjusted EBITDA reflected net income of $3.5 million, compared with $1.4 million in the prior year quarter.
- Cash was $22.3 million at quarter-end, compared with $24.1 million at December 31st, 2025.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to Journey Medical's third quarter 2026 financial results and corporate update conference call. At this time, all participants are in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. Participants of this call are advised that the audio of this conference call is being broadcast live over the internet and is also being recorded for playback purposes. A webcast replay of this call will be available approximately one hour after the end of the call for approximately 30 days. I would now like to turn the conference over to Jaclyn Jaffe, the company's Senior Director of Corporate Operations.
Please go ahead, Jaclyn. Good afternoon, and thank you for participating in today's conference call.
Joining me from Journey Medical's leadership team are Claude Maraoui, Co-Founder, President and Chief Executive Officer, Joseph Benesch, Chief Financial Officer, and Ramsey Alloush, Chief Operating Officer and General Counsel, who will participate in the Q&A portion of the call. During this call, management will be making forward-looking statements, including statements that address, among other things, Journey Medical's expectations for future performance, operational results, financial condition, and the receipt of regulatory approvals. Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements.
For more information about these risks, please refer to the risk factors described in Journey Medical's most recently filed periodic reports on Form 10-K and Form 10-Q, the Form 8-K filed with the SEC today, and the company's press release that accompanies this call, particularly the cautionary statements in it. Today's conference call includes non-GAAP financial measures that Journey Medical believes can be useful in evaluating its performance. You should not consider this additional information in isolation or as a substitute for results prepared in accordance with GAAP. For reconciliation of this non-GAAP financial measure to net loss, its most directly comparable GAAP financial measure, please see the reconciliation table located in the company's earnings press release. The content of this call contains time-sensitive information that is accurate only as of today, Thursday, November 12th, 2026.
Except as required by law, Journey Medical disclaims any obligation to publicly update or revise any information to reflect events or circumstances that occur after this call. It is now my pleasure to turn the call over to Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical.
Thank you, Jaclyn, and good afternoon to everyone on the call today. We continued to make progress in the third quarter, delivering top-line growth and improved profitability during the period. Our total revenue grew by 8% in Q3, with net product sales increasing 11% year-over-year. Net sales of Emrosi were $9 million in the third quarter, up year-over-year and sequentially from the second quarter, driven by higher prescription volume, improving payer reimbursement, and an increase in the number of dermatology writers prescribing the brand. We expect that these key metrics will continue to trend positively in the coming quarters. I am pleased to report that we achieved positive EBITDA for the second consecutive quarter. We remain focused on investing in our proven dermatology commercial infrastructure and driving top-line growth to advance the business toward becoming net earnings and cash flow positive.
Emrosi prescriptions totaled approximately 40,000 in the third quarter, up from about 36,000 total prescriptions in the second quarter of this year. This represents approximately 8% sequential quarterly growth for the product. Importantly, the growth continues to be driven by strong refill demand and the continued ramp in Emrosi prescribers. During the third quarter, the number of unique Emrosi prescription writers grew by approximately 500 to over 5,000 unique prescribers of the product. This number was our internal goal for the year, so we've already reached this objective and are continuing to grow the prescriber base further. We believe that there is critical mass building behind Emrosi and that the value of the brand is continuing to compound as more prescribers and patients experience the product's clinical benefits. With over 14,000 dermatologists in the United States, there is still significant room for us to grow the number of Emrosi prescribers.
A recent addition of five new sales territories is intended to further increase the product's market penetration. With our direct sales professionals, ongoing peer-to-peer marketing activities, and our active presence at key dermatology medical conferences, we are continuing to expand the awareness of Emrosi's superior clinical benefits in the treatment of rosacea. We recently attended the 26th Annual Fall Clinical Dermatology Conference, where we sponsored a poster highlighting clinical data on Emrosi's superior skin-clearing effects. The post-hoc data analysis from our phase III clinical trial showed that nearly 50% of patients that achieved the primary endpoint of investigator global assessment, or IGA success, had complete resolution of their rosacea symptoms at the end of the treatment period with Emrosi. This equates to nearly 30% of the mild to moderate rosacea patients achieving clear skin, or an IGA score of zero with Emrosi treatment.
In comparison, only 12.8% of patients on Oracea achieved an IGA score of zero or completely clear skin. Notably, clinical research shows that rosacea patients who achieve complete symptom clearance experience a significant delay in their time to relapse, and they remain free of symptoms longer than those who reach only partial clearance. With over 2.5 times more patients achieving clear skin with Emrosi compared to Oracea, we believe that these data are compelling and significantly support Emrosi's best-in-class clinical profile. The superior head-to-head efficacy demonstrated in our phase III clinical trials comparing Emrosi to Oracea remains a central message in driving adoption throughout the dermatology community, and these data on complete skin clearance reinforce that message. Emrosi's placebo-like safety and tolerability profile continues to be durable, and this is another important factor in expanding the base of new prescribers.
Additionally, Emrosi's rapid onset of action and superior skin-clearing effects are resonating with patients. Refill rates for Emrosi remain strong, rising nearly 12% from Q2 to Q3, providing a good indication of the high patient satisfaction with the product. In addition to our direct sales efforts, we expect awareness of Emrosi to increase in the market as we plan to announce new journal publications for the product in the coming quarters, and we believe that Emrosi has potential to be incorporated into the consensus treatment guidelines for rosacea. Turning to our activities with payers, we are continuing to make progress with the downstream health plans. The calculated average selling price for Emrosi, based on prescription units, has increased each quarter since the beginning of the year, as reimbursed prescriptions are becoming an increasing part of the business mix.
In addition to working on adding Emrosi to more health plan formularies, we are also pulling through an increased proportion of prescriptions from regions that have more comprehensive formulary coverage. After completing agreements with all of the top three GPOs in the nation earlier this year, our focus remains on pursuing high-quality formulary coverage with the downstream health plans, meaning a single-step edit or better. Currently, 40% of commercial lives have high-quality access to Emrosi. Building on our progress, a large national health plan placed Emrosi on its formulary in early August, and we expect another larger national plan to adopt Emrosi on formulary shortly. Importantly, national plan adoption can have wide-reaching effects, as many smaller regional plans typically model their prescription coverage based on national health plan formularies. With that, I will turn the call over to our CFO, Joseph Benesch, to review our third-quarter financial results.
Thank you, Claude, and good afternoon to everyone on the call. I will now review our financial results for the third quarter of 2026. Total revenue for the quarter was $19 million, compared to $15 million in the third quarter of 2025, an 8% increase from period to period. This growth was primarily driven by the continued commercial demand for Emrosi, which generated $9 million in net revenue for the quarter. Turning to gross margin, we reported a 69% margin for the third quarter of 2026, compared to 67% in the third quarter of 2025, due mainly to Emrosi's lower cost impact on cost of sales. SG&A expenses were $12.6 million for the quarter, compared to $12.1 million in the third quarter of 2025.
The increase was primarily due to a one-time expense of $1.7 million recognized upon the settlement of a dispute with a former vendor. This was partially offset by a reduction in launch-related expenses for Emrosi compared to the prior year quarter. Our GAAP net loss narrowed to $1.3 million, or $0.05 per share basic and diluted, compared to a net loss of $3.9 million, or $0.14 per share basic and diluted, for 3Q 2025. On a non-GAAP basis, both EBITDA and Adjusted EBITDA were positive for the quarter. Notably, Adjusted EBITDA, which is generally our EBITDA number, less non-cash share-based compensation expense, reflected net income of $3.5 million for the third quarter, compared to $1.4 million for the prior year quarter. We ended the quarter with $22.3 million in cash, compared to $24.1 million at December 31, 2025.
Thank you very much. I will now turn the call back over to Claude.
Thank you, Joe. The third quarter was another period of solid performance for the company, as we continued to generate revenue growth and positive EBITDA. Our net product sales grew significantly faster than our expenses, keeping us on path toward becoming sustainably earnings and cash flow positive. Emrosi continues to gain traction in the rosacea treatment market, with growing prescription demand and the base of new prescribers still increasing at an impressive rate. With approximately 40,000 total prescriptions during the third quarter, and now over 5,000 unique prescribers writing for the product, we believe that the brand is becoming widely recognized in the dermatology community. Given Emrosi's superior efficacy profile and potential for the drug to be added to the consensus treatment guidelines, we remain focused on making Emrosi the oral standard of care for rosacea treatment.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
9 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
